Brain

Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business — To Accelerate U.S. Market

Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.aiTo strengthen revenue growth of...

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly...

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation...

DeepHealth Unveils Next-Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025, Advancing a New Standard of AI-Powered Care

Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale—empowering breakthroughs in care through imagingCHICAGO,...

Anabolic Steroids Alternatives: Muscle Building Supplements from CrazyBulk | Most Selling Muscular Endurance Supplements Bodybuilders Use For Peak Performance & Strength Building in 2025

Discover how CrazyBulk’s Anabolic Steroids Alternatives supplements can enhance muscular endurance, boost strength, and speed up recovery. Learn optimal stacks,...

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real...

error: Content is protected !!